CARISMA Therapeutics
(NASDAQ:CARM)
$1.3104
0.0504[4.00%]
At close: May 24
$1.3104
0[0.00%]
After Hours: 9:06AM EDT
Consensus Rating1
Outperform
Highest Price Target1
$12.00
Lowest Price Target1
$6.00
Consensus Price Target1
$9.20

CARISMA Therapeutics Stock (NASDAQ:CARM), Analyst Ratings, Price Targets, Predictions

CARISMA Therapeutics Inc has a consensus price target of $9.2, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and BTIG on May 17, 2024, May 10, 2024, and April 11, 2024. With an average price target of $7.33 between HC Wainwright & Co., HC Wainwright & Co., and BTIG, there's an implied 459.63% upside for CARISMA Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
1
Nov 23
2
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
BTIG
Capital One
Evercore ISI Group
Baird

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for CARISMA Therapeutics

Buy NowGet Alert
05/17/2024Buy Now510.5%HC Wainwright & Co.
Mitchell Kapoor
→ $8ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now510.5%HC Wainwright & Co.
Mitchell Kapoor
$9 → $8MaintainsBuyGet Alert
04/11/2024Buy Now357.88%BTIG
Justin Zelin
→ $6Initiates → BuyGet Alert
04/02/2024Buy Now586.81%HC Wainwright & Co.
Mitchell Kapoor
$11 → $9MaintainsBuyGet Alert
11/29/2023Buy Now739.44%HC Wainwright & Co.
Mitchell Kapoor
→ $11ReiteratesBuy → BuyGet Alert
10/03/2023Buy Now663.13%Capital One
Naureen Quibria
→ $10Initiates → OverweightGet Alert
09/06/2023Buy Now739.44%HC Wainwright & Co.
Mitchell Kapoor
→ $11ReiteratesBuy → BuyGet Alert
08/11/2023Buy Now739.44%HC Wainwright & Co.
Mitchell Kapoor
$10 → $11MaintainsBuyGet Alert
07/06/2023Buy Now815.75%Evercore ISI Group
Liisa Bayko
→ $12Initiates → OutperformGet Alert
06/29/2023Buy Now663.13%HC Wainwright & Co.
Mitchell Kapoor
→ $10ReiteratesBuy → BuyGet Alert
06/28/2023Buy Now663.13%Baird
Jack Allen
→ $10ReiteratesOutperform → OutperformGet Alert
05/24/2023Buy Now663.13%HC Wainwright & Co.
Mitchell Kapoor
→ $10Initiates → BuyGet Alert
04/14/2023Buy Now663.13%Baird
Jack Allen
→ $10Initiates → OutperformGet Alert

FAQ

Q

What is the target price for CARISMA Therapeutics (CARM)?

A

The latest price target for CARISMA Therapeutics (NASDAQ: CARM) was reported by HC Wainwright & Co. on May 17, 2024. The analyst firm set a price target for $8.00 expecting CARM to rise to within 12 months (a possible 510.50% upside). 11 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for CARISMA Therapeutics (CARM)?

A

The latest analyst rating for CARISMA Therapeutics (NASDAQ: CARM) was provided by HC Wainwright & Co., and CARISMA Therapeutics reiterated their buy rating.

Q

When was the last upgrade for CARISMA Therapeutics (CARM)?

A

There is no last upgrade for CARISMA Therapeutics.

Q

When was the last downgrade for CARISMA Therapeutics (CARM)?

A

There is no last downgrade for CARISMA Therapeutics.

Q

When is the next analyst rating going to be posted or updated for CARISMA Therapeutics (CARM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CARISMA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CARISMA Therapeutics was filed on May 17, 2024 so you should expect the next rating to be made available sometime around May 17, 2025.

Q

Is the Analyst Rating CARISMA Therapeutics (CARM) correct?

A

While ratings are subjective and will change, the latest CARISMA Therapeutics (CARM) rating was a reiterated with a price target of $0.00 to $8.00. The current price CARISMA Therapeutics (CARM) is trading at is $1.31, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch